On August 12, 2026, clinicaltrials.gov listed an update for a trial involving dulaglutide. The study, titled "Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes," is registered under identifier NCT05478707. Its current status is recruiting. The trial is listed as Phase 2.
The registry entry does not provide results or outcome data at this time. No efficacy or safety conclusions are included in this update. The listing reflects only the trial's registration status, phase, and recruitment stage as of the date given.
Dulaglutide is an approved compound, and this trial represents ongoing clinical research rather than a change in its approval status. Details on trial design, eligibility, and endpoints are available through the official registry listing linked with this update.
Readers seeking further context on dulaglutide, including its approved uses and general background, can consult the compound overview.